ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know
ANI Pharmaceuticals (ANIP) closed the latest trading day at $57.44, indicating a +0.23% change from the previous session's end. This move outpaced the S&P 500's daily loss of 1.26%. On the other hand, the Dow registered a loss of 0.86%, and the technology-centric Nasdaq decreased by 1.54%.
The the stock of drugmaker has fallen by 3.4% in the past month, leading the Medical sector's loss of 4.83% and the S&P 500's loss of 3.67%.
Market participants will be closely following the financial results of ANI Pharmaceuticals in its upcoming release. The company's earnings per share (EPS) are projected to be $0.76, reflecting a 18.75% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $108.18 million, indicating a 29.06% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.94 per share and a revenue of $446.5 million, signifying shifts of +189.71% and +41.13%, respectively, from the last year.
Investors should also note any recent changes to analyst estimates for ANI Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 1.58% lower. Right now, ANI Pharmaceuticals possesses a Zacks Rank of #3 (Hold).
Looking at valuation, ANI Pharmaceuticals is presently trading at a Forward P/E ratio of 14.55. This represents a discount compared to its industry's average Forward P/E of 16.45.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 80, positioning it in the top 32% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
